BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.67 +1.17%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst Pharma (BCRX) Tops Q3 EPS by 5c ; Offers Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
